Observational studyWomen's health (London, England)
Characteristics and health factors influencing menstrual changes after COVID-19 vaccination: A Spanish retrospective observational study in currently menstruating women.
Observational study in Women's health (London, England). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is increasing evidence that menstrual changes (MC) should be considered as an adverse event resulting from COVID-19 vaccination. However, the contributing health factors are still poorly understood.
objectivesThe aim was to analyze the characteristics and factors influencing MC after the administration of the severe acute respiratory syndrome coronavirus 2 vaccine. DESIGN &
methodsA retrospective observational study of currently menstruating women (
results45.0%-50.9% of respondents reported experiencing mostly transient MC after both doses of COVID-19 vaccine, including different spotting (41.6%-49.0%), longer periods (26.5%-29.5%) and/or heavier flow (28.7%-31.6%). Binary logistic regression analysis showed that some of the inter-individual factors that may be involved in this unexpected event are age (dose 2: adjusted odds ratio (aOR): 1.02; 95% confidence intervals (CI): 1.02-1.03), heavy menstrual flow (dose 1: aOR: 1.12; 95% CI: 1.00-1.25), use of short- (dose 1: aOR: 1.38; 95% CI: 1.24-1.54) to medium-term contraception (dose 1: aOR: 1.31; 95% CI: 1.09-1.57), number of previous pregnancies (dose 1: aOR: 1.11; 95% CI: 1.03-1.19), pre-existing diagnoses of certain clinical conditions-including endometriosis (dose 1: aOR: 1.33; 95% CI: 1.11-1.59)-and suffering from other vaccine adverse events.
conclusionCurrently menstruating women may experience MC after COVID-19 vaccination. Further research is warranted to address the influencing factors, considering their heterogeneity according to the geographical background of the target population. This kind of evidence could prove instrumental in the context of future viral outbreaks, helping healthcare professionals to provide scientifically up-to-date information to patients for making informed decisions regarding their well-being, particularly in societies where menstruation remains a taboo subject.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.